Press releases

Neopharmed Gentili S.p.A. | Via S.G.Cottolengo, 15 20143 Milano | C.F. e P.I 06647900965
Iscrizione registro imprese di Milano n. 1905235 | Capitale sociale € 1.161.212,00

Disclaimer

This announcement does not constitute an offer to sell or the solicitation of an offer to buy the Notes or any other security and shall not constitute an offer, solicitation or sale in the United States or in any jurisdiction in which, or to any persons to whom, such offering, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any jurisdiction.

The securities are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any retail investor in the EEA. For these purposes, a retail investor means a person who is one (or more) of: (i) a retail client as defined in point (11) of Article 4(1) of Directive 2014/65/EU (as amended, “MiFID II”); (ii) a customer within the meaning of Directive 2016/97/EU (as amended), where that customer would not qualify as a professional client as defined in point (10) of Article 4(1) of MiFID II; or (iii) not a “qualified investor” as defined in Regulation (EU) 2017/1129 (as amended). Consequently, no key information document required by Regulation (EU) No 1286/2014 (as amended, the “PRIIPs Regulation”) for offering, selling or distributing the securities or otherwise making them available to retail investors in the EEA has been prepared and therefore offering or selling the securities or otherwise making them available to any retail investor in the EEA may be unlawful under the PRIIPS Regulation.

In member states of the EEA, this announcement and any offer of the securities referred to herein in any Member State of the European Economic Area (“EEA”) will be made pursuant to an exemption under the Prospectus Regulation from the requirement to publish a prospectus for offers of the securities referred to herein. Accordingly, any person making or intending to make an offer in a Member State of Notes which are the subject of the offering contemplated may only do so in circumstances in which no obligation arises for the Issuers or any of the initial purchasers to publish a prospectus pursuant to Article 3 of the Prospectus Regulation, in each case, in relation to such offer. Neither the Issuer nor the initial purchasers have authorized, nor do they authorize, the making of any offer of Notes in circumstances in which an obligation arises for the Issuers or the initial purchasers to publish a prospectus for such offer. The expression “Prospectus Regulation” means Regulation (EU) 2017/1129.

The securities are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any retail investor in the United Kingdom (“UK”). For these purposes, a retail investor means a person who is one (or more) of: (i) a retail client, as defined in point (8) of Article 2 of Regulation (EU) No 2017/565 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 (“EUWA”); (ii) a customer within the meaning of the provisions of the FSMA and any rules or regulations made under the FSMA to implement Directive (EU) 2016/97, where that customer would not qualify as a professional client, as defined in point (8) of Article 2(1) of Regulation (EU) No 600/2014 as it forms part of domestic law by virtue of the EUWA; or (iii) not a “qualified investor” as defined in Article 2 of the Prospectus Regulation as it forms part of UK domestic law by virtue of the EUWA (the “UK Prospectus Regulation”). Consequently no key information document required by Regulation (EU) No 1286/2014 as it forms part of domestic law by virtue of the EUWA (the “UK PRIIPs Regulation”) for offering or selling the Notes or otherwise making them available to retail investors in the UK has been prepared and therefore offering or selling the Notes or otherwise making them available to any retail investor in the UK may be unlawful under the UK PRIIPs Regulation.

In the UK, this announcement and any offer of the securities referred to herein in the UK will be made pursuant to an exemption under the UK Prospectus Regulation from the requirement to publish a prospectus for offers of the securities referred to herein. Accordingly, any person making or intending to make an offer in the UK of Notes which are the subject of the offering contemplated may only do so in circumstances in which no obligation arises for the Issuers or any of the initial purchasers to publish a prospectus pursuant to Article 3 of the UK Prospectus Regulation, in each case, in relation to such offer. Neither the Issuer nor the initial purchasers have authorized, nor do they authorize, the making of any offer of Notes in circumstances in which an obligation arises for the Issuers or the initial purchasers to publish a prospectus for such offer. The expression “UK Prospectus Regulation” means Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the EUWA.

This communication is being distributed only to, and is directed at persons who (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Financial Promotion Order”) (ii) are persons falling within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Promotion Order, (iii) are outside the United Kingdom or (iv) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000 in connection with the issue and sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as “relevant persons”). This announcement is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this announcement relates is available only to relevant persons and will be engaged in only with relevant persons.

The securities will not be listed on an Italian regulated market, therefore no documents or materials relating to the securities have been or will be submitted to the clearance procedure of the competent authority.

Each subsequent page should bear the legend:

Not for release, publication or distribution, directly or indirectly, in the United States, the United Kingdom, Canada, Australia or Japan or in any other jurisdiction in which offers or sales would be prohibited by applicable law.

Disclaimer

IMPORTANT NOTICE: You must read the following information before continuing.
Access to the information and documents on the portion of our website that follows this disclaimer (the “IR Section”) is restricted for regulatory reasons. By accessing the IR Section you will be deemed to have read and accepted the terms of this disclaimer. The information contained in the IR Section and in the reports, financial statements, press releases, presentations and other documents available in the IR Section (the “Information”) does not constitute an offer to sell or a solicitation of an offer to buy any securities of Neopharmed S.p.A. (the “Company”) or any of its subsidiaries or affiliates. You must comply with all laws that apply to you in any place in which you buy, offer or sell any securities or access or possess the Information.
Any securities referred to in the Information have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) and may be offered or sold only to investors who are either (i) qualified institutional buyers (within the meaning of Rule 144A under the Securities Act) in the United States or (ii) outside the United States in offshore transactions in accordance with Regulation S under the Securities Act (and, if investors are resident in a member state of the European Economic Area, a qualified investor, within the meaning of Article 2(e) of Regulation (EU) 2017/1129, as amended, and any relevant implementing measure in each member state of the European Economic Area).
You acknowledge that the information and statements contained in the document you are accessing on this website speak only as of the date of such document (or such other date(s) specified therein), and such information and statements may become inaccurate, stale and/or out-of-date thereafter and should not be relied upon for any investment decision. You acknowledge that the materials on this website that you are accessing are confidential and intended only for you and you agree you will not forward, reproduce, copy, download or publish any of such materials (electronically or otherwise) to any other person if this is not in accordance with the law. You acknowledge that the access to information and documents contained on this portion of the website may be illegal in certain jurisdictions, and only certain categories of persons may be authorized to access this portion of the website. If you are not authorized to access the information and document contained on this portion of the website or you are not sure that you are permitted to view these materials, you should leave this portion of the website.
You acknowledge that no registration or approval has been obtained and the Company and its affiliates assume no responsibility if there is a violation of applicable law and regulation by any person.
By clicking the button below labeled “Yes”, you are confirming that you have read and understood the disclaimer above.
If you cannot so confirm, you must click the button labelled “No” or otherwise exit this portion of the website.

Press releases

November 07, 2024

Neopharmed Gentili S.p.A. – Financial Results for Q3 2024

July 18, 2024

Neopharmed Gentili S.p.A. announces CEO transition

20 Marzo 2024

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Praesent eget arcu iaculis nisi commodo ultricies.

July 8, 2024

Neopharmed Gentili S.p.A. – Financial Results for Q2 2024

20 Marzo 2024

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Praesent eget arcu iaculis nisi commodo ultricies.

June 4, 2024

Neopharmed Gentili S.p.A. – Financial Results for Q1 2024

20 Marzo 2024

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Praesent eget arcu iaculis nisi commodo ultricies.

May 16, 2024

Neopharmed Gentili S.p.A. – Creation of first ranking pledge over the share capital of Neopharmed Gentili S.p.A. and Valeas S.p.A.

20 Marzo 2024

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Praesent eget arcu iaculis nisi commodo ultricies.

March 28, 2024

Neopharmed Gentili S.P.A. successfully completes the placement of its €750.0 million senior secured notes due 2030

20 Marzo 2024

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Praesent eget arcu iaculis nisi commodo ultricies.